Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aileron Therapeutics Inc (ALRN)

Aileron Therapeutics Inc (ALRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,763
  • Shares Outstanding, K 4,885
  • Annual Sales, $ 0 K
  • Annual Income, $ -27,330 K
  • 60-Month Beta 2.22
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.40
Trade ALRN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.82
  • Growth Rate Est. (year over year) +121,929.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.12 +21.36%
on 04/17/24
7.42 -32.61%
on 04/18/24
-0.41 (-7.58%)
since 03/18/24
3-Month
3.78 +32.28%
on 01/19/24
7.42 -32.61%
on 04/18/24
+0.77 (+18.20%)
since 01/18/24
52-Week
1.01 +395.05%
on 10/31/23
7.42 -32.61%
on 04/18/24
+3.36 (+204.88%)
since 04/18/23

Most Recent Stories

More News
Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now

After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in earnings...

ALRN : 5.00 (+17.65%)
Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Aileron Therapeutics, Inc. (ALRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement...

ALRN : 5.00 (+17.65%)
What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock

Aileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ALRN : 5.00 (+17.65%)
Aileron Therapeutics, Inc. (ALRN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Aileron Therapeutics, Inc. (ALRN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions...

ALRN : 5.00 (+17.65%)
Aileron Therapeutics, Inc. (ALRN) Moves to Buy: Rationale Behind the Upgrade

Aileron Therapeutics, Inc. (ALRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ALRN : 5.00 (+17.65%)
Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer

Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced...

ALRN : 5.00 (+17.65%)
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022

BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer...

ALRN : 5.00 (+17.65%)
Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93% of cycles on ALRN-6924...

ALRN : 5.00 (+17.65%)
Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicitiesTrial...

ALRN : 5.00 (+17.65%)
Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022

BOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer...

ALRN : 5.00 (+17.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers...

See More

Key Turning Points

3rd Resistance Point 9.69
2nd Resistance Point 8.55
1st Resistance Point 6.78
Last Price 5.00
1st Support Level 3.87
2nd Support Level 2.73
3rd Support Level 0.96

See More

52-Week High 7.42
Last Price 5.00
Fibonacci 61.8% 4.97
Fibonacci 50% 4.22
Fibonacci 38.2% 3.46
52-Week Low 1.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar